Natalizumab Injection 300 mg Suppliers & Bulk Manufacturers
Available Forms: IV Injection
Available Strengths: 300 mg
Reference Brands: Tysabri(US & EU)
Category: Multiple sclerosis
Natalizumab is a monoclonal antibody that blocks α4-integrin, preventing immune cells from crossing the blood-brain barrier. It reduces inflammation, decreases MS relapses, and slows disease progression. Benefits include effective disease control, fewer relapses, and improved quality of life for patients with relapsing multiple sclerosis.
Product Description:
Natalizumab injection, marketed as Tysabri, is approved in the US by the FDA and in the EU via EMA for multiple sclerosis and Crohn’s disease. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and safety data, while the EMA ensures compliance with regional safety and quality standards.
Natalizumab Injection — third party manufacturing & bulk supply
Natalizumab Injection 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Natalizumab Injection is supplied as IV Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Natalizumab Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Natalizumab Injection →Frequently Asked Questions
Natalizumab is used for treating relapsing forms of multiple sclerosis (MS) to reduce the frequency of relapses and delay disability progression. It is also used for moderate to severe Crohn’s disease in adults who have not responded adequately to conventional therapies.
Natalizumab is a humanized monoclonal IgG4 antibody that binds to the α4 subunit of integrins on leukocytes, blocking their adhesion to vascular endothelium and preventing migration into the central nervous system and inflamed intestinal tissue.
Tysabri.
Biogen Inc. (co-developed with Elan Pharmaceuticals).
Natalizumab.
Tysabri.
Manufactured in the USA and distributed globally, including the EU, Japan, and other regions.
Related Products
Ocrelizumab Injection
Strength:
300 mg
Form: Injection
Reference Brands: Ocrevus(EU & US)
View Details
Alemtuzumab Injection
Strength:
12 mg/1,2 ml
Form: Injection
Reference Brands: Lemtrada(US & EU)
View Details
Teriflunomide Tablets
Strength:
7 mg and 14 mg tablets
Form: Tablet
Reference Brands: Aubagio(US & EU)
View Details
Siponimod Tablets
Strength:
2 mg tablets
Form: Tablet
Reference Brands: Mayzent(US &EU)
View Details
Ofatumumab Injection
Strength:
20 mg/mL
Form: Injection(SQ)
Reference Brands: Kesimpta(US)
View DetailsQuick Response Guaranteed | Verified Suppliers
